Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Thursday, April 21. 2016
Basel, Switzerland, April 21, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that the shareholders approved all agenda items proposed by the Board of Directors at today's Ordinary General Meeting of Shareholders (AGM) for the financial year 2015. At the meeting, 33.2 percent of Basilea's share capital was represented.
Thursday, April 21. 2016
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models
Wednesday, April 20. 2016
Basel, Switzerland, April 20, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has entered into a contract with Basilea Pharmaceutica International Ltd. ("Basilea") for the clinical phase 3 development aiming at regulatory approval of Basilea's broad-spectrum antibiotic ceftobiprole in the United States.
Friday, April 15. 2016
  • Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia

Quick links:

Investor calendar
Upcoming events

News subscription
Press releases via e-mail

French Sunshine Act
Transparence des liens d’intérêt